Keryx Biopharmaceuticals (KERX) 10-Q2004 Q1 Quarterly report

Filed: 14 May 04, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accreted, accretion, added, agent, AICPA, Aid, aimed, albumin, American, amortization, amortized, andDecember, assimilating, assist, assumption, aware, AXO, build, carefully, cautionary, check, client, combination, combined, Commission, communicated, community, constitute, Cooperative, corrective, coverage, CRADA, credit, declared, deliverable, delivery, demonstrated, department, deposit, difficulty, discount, disease, Dividend, DNA, earned, Electronic, EmployerIdentification, enforcing, entirety, entitled, entity, equal, equaling, eventual, excretion, expressed, expressly, face, flexibility, Food, growth, harbor, health, heparin, higher, III, inability, inaccurate, increasingly, inhibitor, injury, insurance, intercompany, investor, issuable, Journal, kidney, Kingdom, lengthy, lesser, mark, marketplace, meaningful, merit, modestly, monthsended, multiplied, National, Navelbine, NCI, NDA, NIH, Noo, Nox, OCOG, oncology, Online, oral, Panmure, participation, pathological, payable, payment, payor, penetration, Perifosine, pipeline, pivotal, poison, preliminarily, preliminary, prepayment, project, publicly, published, purport, rata, recall, Reform, registered, reimbursement, repair, reputation, retroactively, Roth, safe, safer, salary, show, showed, single, site, situation, Society, specific, specifically, spindle, staffing, structured, subordinated, supervision, support, surviving, sustained, target, Taxol, Taxotere, tempting, tumor, unconsolidated, unfavorable, unissued, urinary, variety, WestLB, withdrawal, Yesx, yield

Removed: Add, approximate, assessing, authorized, behalf, Certification, chance, close, Commonwealth, comparable, Compounding, comprehensive, computing, confidence, consulting, consumer, continued, cumulative, currency, daily, decided, decision, Deduct, dependency, designed, determination, disclaim, disposal, disposed, dollar, dramatic, duly, economic, EMPLOYER, entry, estimating, expensed, expire, fallen, fewer, force, formal, functional, gain, gave, IDENTIFICATION, implementation, important, inflation, intangible, intention, introduced, JURISDICTION, left, linked, local, located, lower, met, minimal, negatively, NIS, noted, notification, obligation, open, parent, person, political, preclinical, Recoverability, recoverable, reevaluated, reorganization, review, revise, REVISED, royalty, separate, terrorist, thereof, thereunto, transact, translate, translated, translation, undersigned, unease, update, waned, work, wrong

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

KERX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

STATEMENT OF CHIEF EXECUTIVE OFFICER OF
KERYX BIOPHARMACEUTICALS, INC.
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Keryx Biopharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2004 as filed with the Securities and Exchange Commission (the “Report”), I, Michael S. Weiss, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 14, 2004		/s/ Michael S. Weiss
		Michael S. Weiss Chief Executive Officer (Principal Executive Officer)